SGP-101

SGP-101 is a drug candidate that has been investigated primarily as a diagnostic imaging agent or therapeutic for specific conditions, though it is often associated with early-stage research. In some contexts, SGP-101 refers to a formulation or compound developed for the treatment of dermatological or inflammatory conditions, or as a targeted imaging probe. Due to the ambiguity of the 'SGP' acronym in the pharmaceutical literature, it is most frequently identified in clinical pipelines as a specific investigational product by developers like Semorelin or similar biotech entities. It typically functions by targeting specific cellular receptors or metabolic pathways to provide either a therapeutic effect or a high-contrast signal for medical imaging.

Other names

SGP-101SGP101SGP 101